Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

Fed Circuit backs Eli Lilly in Apotex’s appeal over failed Alimta NDA
Americas
The US Court of Appeals for the Federal Circuit yesterday, December 21, upheld Eli Lilly’s success in barring the sale of a copycat version of cancer treatment Alimta (pemetrexed disodium).   22 December 2020
Amgen faces struggle to revive cholesterol patents, says Fed Circ judge
Pharma
Amgen is unlikely to succeed in its bid to revive its patents for the cholesterol drug Repatha, a judge at the US Court of Appeals for the Federal Circuit has told the pharmaceutical company.   14 December 2020
90% of essential medicines off-patent, study reveals
Pharma
Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.   10 December 2020
Americas
Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.   8 December 2020
Americas
Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.   7 December 2020
Americas
The US Immigration and Customs Enforcement has unveiled the next stage of its operation to combat a wave of fraudulent vaccines and treatments, after seizing more than $26 million in illicit proceeds from COVID-19 related products over the past six months.   2 December 2020
Biotech
The UK Competition and Markets Authority is investigating Essential Pharma over suspicions that the pharmaceutical company contravened competition law by proposing to withdraw the supply of Priadel, a lithium-based medication for bipolar disease.   30 November 2020
article
The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.   26 November 2020
Americas
The US Department of Health and Human Services will reveal more information regarding its licensing of IP to private companies for drug development, it has confirmed in a letter to a congressional watchdog.   26 November 2020
Americas
Philips was not anti-competitive when it refused a medical equipment maintenance company access to its software for ultrasound machines but did misuse its copyright, the US District Court for the Western District of Washington has ruled.   24 November 2020

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.